

PUBLICACIONES DR. RODRIGO ALONSO

- Suades R, Padró T, **Alonso R**, López-Miranda J, Mata P, Badimón L. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in Familial hypercholesterolemia patients. *Thromb Haemost.* 2014; 111: 111-21.
- Watts GF, Gidding S, Wierzbicki A, Toth PP, **Alonso R**, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *Int J Cardiol* 2014; 171:309-25
- Watts GF, Gidding S, Wierzbicki AS, Toth PP, **Alonso R**, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *J Clin Lipidol.* 2014;8:148-72
- **Alonso R**, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, et al; Lipoprotein(a) levels in Familial Hipercholesterolaemia: an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation. *J Am Coll Cardiol.* 2014; 63:1982-9.
- Cubedo J, Padró T, Cinca J, Mata P, **Alonso R**, Badimon L. Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. *Eur J Clin Invest.* 2014;44:266-75.
- Watts GF, Gidding S, Wierzbicki AS, Toth PP, **Alonso R**, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *Eur J Prev Cardiol.* 2014 Apr 28. [Epub ahead of print]
- Watts GF, Gidding S, Wierzbicki AS, Toth PP, **Alonso R**, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. *J Atheroscler Thromb.* 2014;21:368-74.

- Mata P, **Alonso R**, Ruíz-García A, Díaz-Díaz JL, González N, Gijón-Conde T, Martínez-Faedo C, Morón I, Arranz E, Aguado R, Argueso R, Perez de Isla L. Familial combined hyperlipidemia: Consensus document. *Aten Primaria*. 2014 46:440-6.
- Sánchez Muñoz-Torero JF, Rivas MD, Zamorano J, **Alonso R**, Joya Vazquez P, et al. rs1801275 Inteleukin-4 receptor alpha polymorphism in familial Hypercholesterolemia. *J Clin Lipidol* 2014;8:418-22.
- Mata P, **Alonso R**, Ruíz-García A, Díaz-Díaz JL, González N, Gijón-Conde T, Martínez-Faedo C, Morón I, Arranz E, Aguado R, Argueso R, Perez de Isla L. Familial combined hyperlipidemia: Consensus document. *Semergen* 2014 40:374- 80
- Mata P, **Alonso R**, Pérez-Jiménez F. Screening for Familial Hypercholesterolemia: a Model for Preventive Medicine. *Rev Esp Cardiol* 2014;67:685-8.
- Cuevas A, Farías MM, **Alonso R**. New Lipid Lowering Agents. *Rev Med Chile* 2014;142:880-8
- Mata P, **Alonso R**, Ruiz A, Gonzalez-Juanatey JR, Badimón L, Díaz-Díaz JL, Muñoz MT, Muñiz O, Galve E, Irigoyen L, Fuentes-Jiménez F, Dalmau J, Pérez- Jiménez F; otros colaboradores. Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document. *Semergen*. 2015; 41:24-33
- Mata P, **Alonso R**, Ruiz A, Gonzalez-Juanatey JR, Badimón L, Díaz-Díaz JL, Muñoz MT, Muñiz O, Galve E, Irigoyen L, Fuentes-Jiménez F, Dalmau J, Pérez- Jiménez F; Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document. *Aten Primaria*. 2015;47:56-65.
- Aledo R, Padró T, Mata P, **Alonso R**, Badimón L. Rs11613352 Polymorphism (TT Genotype) associates with a decrease of triglycerides and an increase of HDL in Familial Hypercholesterolemia patients. *Rev Esp Cardiol* 2015;68:305-9.
- Cerrato F, Fernández-Suárez ME, **Alonso R**, Alonso M, Vázquez C, Pastor O, Mata P, Lasunción MA, Gómez-Coronado D. Clinically used selective estrogen receptor modulators increases LDL receptor activity in primary human lymphocytes. *Br J Pharmacol*. 2015;172: 1379-94.
- **Alonso R**, Mata P, Alonso Y Gregorio M, de Andrés R. Homozygous familial

hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B. *Med Clin (Barc)*. 2015;145:229-30.

- Suades R, Padró T, **Alonso R**, Mata P, Badimon L. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. *Thromb Haemost*. 2015 Jul;114(5).
- Roeters van Lennep J, Aversa M, **Alonso R**. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. *J Clin Lipidol*. 2015;9:607-17.
- Fuentes F, Alcalá-Díaz J, Watts G, **Alonso R**, Muñiz O, Díaz-Díaz JL, et al. Stains do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. *Int J Cardiol* 2015;201:79-84.
- Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Akram A, Alnouri F, **Alonso R**, et al. Familial Hypercholesterolaemia: A global call to arms. *Atherosclerosis*. 2015;243:257-9.
- Pérez de Isla L, **Alonso R**, Watts G, Mata N, Saltijeral A, Muñiz O, Fuentes F, Díaz-Díaz JL, de Andrés R, Zambón D, Rubio-Martín P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martínez-Faedo C, Miramontes-gonzález JP, Badimón L, Mata P. Attainment of LDL cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. *J Am Coll Cardiol*. 2016;67:1278-85
- Cubedo J, Padró T, **Alonso R**, Mata P, Badimon L. ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia. *J Lipid Res*. 2016;57:1059-73.
- de Isla LP, Cerezo AS, **Alonso R**, Mata P. Lipoprotein(a) and familial hypercholesterolaemia. *Lancet Diabetes Endocrinol*. 2016;8587:30149-8.
- Pérez de Isla L, **Alonso R**, Mata N, et al. SAFEHEART Investigators. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). *Arterioscler Thromb Vasc Biol*. 2016;36:2004-16.

- **Alonso R**, Díaz-Díaz JL, Arrieta F et al. Clinical and Molecular Characteristics of Homozygous Familial Hypercholesterolemia Patients: Insights from SAFEHEART Registry. *J Clin Lipidol* 2016;10:953-61.
- **Alonso R**, Mata P, Muñoz O, Fuentes-Jimenez F, Díaz JL, Zambón D, Tomás M, Martín C, Moyon T, Croyal M, Thédrez A, Lambert G. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. *Atherosclerosis* 2016; 254:249-53.
- EAS Familial Hypercholesterolaemia Studies Collaboration., Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Freiburger T, Abifadel M, Aguilar-Salinas CA, Alnouri F, **Alonso R**, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. *Atheroscler Suppl.* 2016;22:1-32
- Saltijeral A, Pérez de Isla L, **Alonso R**, Muñoz O, Díaz-Díaz JL, Fuentes F, Mata N, de Andrés R, Díaz-Soto G, Pastor J, Pinilla JM, Zambón D, Pinto X, Badimón L, Mata P; SAFEHEART Investigators. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry. *Rev Esp Cardiol.* 2017;70:444-450
- Sposito AC, Faria Neto JR, Carvalho LS, Lorenzatti A, Cafferata A, Elikir G, Esteban E, Morales Villegas EC, Bodanese LC, **Alonso R**, et al ; on behalf of the Luso-Latin American Consortium on Statin-Associated Muscle Symptoms. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. *Curr Med Res Opin.* 2017;33:239-51.
- Croyal M, Fall F, Krempf M, Thédrez A, Ouguerram K, Ferchaud-Roucher V, Aguesse A, Billon-Crossouard S, Mata P, **Alonso R**, et al. PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2017;1044-1045:24-29.
- Pérez de Isla L, **Alonso R**, Mata N, Fernández-Pérez C, Muñoz O, Díaz-Díaz JL, et al; SAFEHEART investigators. Predicting Cardiovascular Events in Familial

Hypercholesterolemia: The SAFEHEART Registry. *Circulation* 2017;135:2133-44

- Santos RD, Bourbon M, **Alonso R**, et al ; Ibero-American Familial Hypercholesterolemia Network. Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. *J Clin Lipidol.* 2017;11:160-6.
- Bourbon M, Alves AC, **Alonso R**, Mata N, Aguiar P, Padro T, Mata P. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. *Atherosclerosis* 2017;262:8-13.
- Lázaro P, Pérez de Isla L, Watts GF, **Alonso R**, et al . Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. *J Clin Lipidol.* 2017;11:260-71
- Ponte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, Lopez-Jaramillo P, Wyss-Q FS, Pintó X, Lanas F, Medina J, Machado-H LT, Acevedo M, Varleta P, Bryce A, Carrera C, Peñaherrera CE, Gómez-M JR, Lozada A, Merchan-V A, Piskorz D, Morales E, Paniagua M, Medina-Palomin F, Villar-M RA, Cobos L, Gómez-Alvares E, **Alonso R**, et al. Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS). *Int J Cardiol.* 2017 Sep 15;243:516-522.
- Berry MA, Urrutia L, Lamoza P, Molina A, Luna E, Parra F, Domínguez MJ, **Alonso R**. Sleeve gastrectomy outcomes in patients with BMI between 30 and 35-3 years of follow-up. *Obes Surg.* 2018;28:649-55
- Pérez de Isla L, **Alonso R**, Muñiz-Grjalvo O, Díaz-Díaz- JL, et al. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. *J Clin Lipidol* 2018;12:948-57.
- EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiburger T, Hovingh GK, Kastelein JJP, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Al-

Khnefawi M, AlKindi FA, Alnouri F, **Alonso R**, et al; EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators. Overview of the current status of familial hypercholesterolaemia care in over 60 countries- The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Atherosclerosis. 2018 Oct;277:234-255.

- **Alonso R**, Perez de Isla L, Muñiz O, Diaz-Diaz JL, Mata P. Familial Hypercholesterolemia diagnosis and management. *Eur Cardiol* 2018; 13:14-20.
- Mata P, **Alonso R**, Pérez de Isla L. Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?. *Curr Opin Lipidol* 2018;29:445-52
- Pérez de Isla L, **Alonso R**, Mata P. Response to letter entitled “Coronary computed tomography angiogram in familial hypercholesterolemia: A double edge sword” by Dr. Sam Mirzaee and Dr James D Cameron. *J Clin Lipidol* 2018;12_1549-50
- **Alonso R**, Cuevas A, Cafferata A. Diagnosis and management of Statin intolerance. *J Atheroscler Thromb* 2019;26:207-15
- Arroyo- Olivares R, **Alonso R**, Quintana Navarro G, Fuentes-Jiménez F, Mata N, Muñiz-Grijalvo O, et al. Adults with familial hypercholesterolemia have healthier dietary habits and lifestyle habits compared with their non-affected relatives: The SAFEHEART study. *Public Health Nutr* 2019; Feb 8-11: doi: 10.1017/S1368980018003853
- Ellis KL, Pérez de Isla L, **Alonso R**, Fuentes F, Watts GF, Mata P. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. *J Am Coll Cardiol* 2019;73:1029-39
- Suades R, Padró T, Crespo J, Sionis A, **Alonso R**, Mata P, Badimón L. Liquid biopsy of extracellular microvesicles predicts future major ischemic events in genetically characterized familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol* 2019;39:1172-81
- Miramontes-Gonzalez JO, Usategui-Martin R, Perez de Isla L, **Alonso R**, Muliz Grijalvo O, Diaz Diaz JL, Sarmiento R, Mata P. VEGFR2 and OPG genes modify the

risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. *Atherosclerosis* 2019;285:17-22

- Chiva-Blanch G, Padro T, **Alonso R**, Crespo J, Pérez de Isla L, Mata P, Badimón L. Liquid biopsy of extracellular microvesicles Maps Coronary calcification and Atherosclerotic plaque in asymptomatic patients with familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol* 2019;39:1172-81
- Perez de Isla L, Ray KK, Watts G, Santos R, **Alonso R**, Muñiz-Grijalvo O, Diaz Diaz JL, Badimon L, Catapano AL, Mata P. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. *Atherosclerosis* 2019;286:40-45
- Pérez de Isla L, Arroyo-Olivares R, Muñiz-Grijalvo O, Diaz-Díaz JL, Zambón D, Fuentes F, Sánchez Muñoz-Torrero JF, Mediavilla JD, González-Estrada A, Miramontes-González JP, de Andrés R, Mauri M, Mosquera D, Cepeda JM, Suárez L, Barba-Romero MÁ, Argüeso R, Álvarez-Baños P, Michán A, Romero-Jiménez MJ, García-Cruces J, Padró T, **Alonso R**, Mata P. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. *J Clin Lipidol* 2019;13:989-97
- **Alonso R**, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. *Core Evid* 2019;14:19-30
- Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, **Alonso R**, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. *JAMA Cardiol* 2020 Jan 2. Doi:10.1001/jamacardiol.2019.5173
- **Alonso R**, Perez de Isla L, Muñiz-Grijalvo O, Mata P. Barriers to Early Diagnosis and Treatment of Familial Hypercholesterolemia: Current Perspectives on Improving Patient Care. *Vasc Health Risk Manag* 2020 16:11-25.